m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00666
 [1], [2], [3]
m6A modification MIR20A MIR20A HNRNPA2B1 : m6A sites Indirect Enhancement RNA modification RRM2 RRM2 YBX1 : modification sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) READER
 Regulator Info 
m6A Target hsa-mir-20a
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> 5-methylcytidine (m5C)
Epigenetic Regulator Y-box-binding protein 1 (YBX1) READER View Details
Regulated Target Ribonucleotide reductase regulatory subunit M2 (RRM2) View Details
Crosstalk Relationship m6A  →  m5C Enhancement
Crosstalk Mechanism m6A modification indirectly impacts RNA modification through downstream signaling pathways
Crosstalk Summary HNRNPA2B1 interacts with hsa-mir-20a, reading its m6A level and promoting its physical interaction with Ribonucleotide reductase regulatory subunit M2 (RRM2), which was regulated by YBX1-mediated m5C modification.
In-vitro Model
TE1
 N.A. Mus musculus CVCL_C6K3
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Ribonucleotide reductase regulatory subunit M2 (RRM2) 9 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Gemcitabine Approved [4]
Synonyms
Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)
    Click to Show/Hide
MOA Modulator
External Link
CID: 60750
TTD: D03UVS
DrugBank: DB00441
 Compound Name Hydroxyurea Approved [4]
Synonyms
Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA
    Click to Show/Hide
MOA Modulator
External Link
CID: 3657
TTD: D07CWD
DrugBank: DB01005
 Compound Name Triapine Phase 2 [5]
Synonyms
236392-56-6; 143621-35-6; 3-Apct; Pan 811; 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP; UNII-U4XIL4091C; NSC 663249; 200933-27-3; OCX 191; 2-((3-Aminopyridin-2-yl)methylene)hydrazinecarbothioamide; C7H9N5S; PAN-811; U4XIL4091C; 3-aminopyridine-2-carbaldehyde-thiosemicarbazone; [(E)-(3-amino-2-pyridyl)methyleneamino]thiourea; 3-Aminopyridine-2-carboxaldehyde- thiosemicarbazone; Hydrazinecarbothioamide, 2-((3-amino-2-pyridinyl)methylene)-; (E)-2-((3-aminopyridin-2-yl)methylene)hydrazinecarbothioamide
    Click to Show/Hide
MOA Modulator
Activity IC50 = 185 nM
External Link
CID: 9571836
TTD: D0DT1R
DrugBank: DB11940
 Compound Name CO-101 Phase 2 [6]
Synonyms
methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9828310
TTD: D0V0CJ
DrugBank: DB12564
 Compound Name CALAA-01 Phase 1 [7]
Synonyms
Ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer), Calando
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0A1GR
 Compound Name LY-2334737 Phase 1 [8]
Synonyms
Gem prodrug (cancer), Eli Lilly; Gemcitabine prodrug (cancer), Lilly
    Click to Show/Hide
MOA Modulator
External Link
CID: 11646777
TTD: D0F2JY
DrugBank: DB12906
 Compound Name Gallium maltolate Discontinued in Phase 2 [9]
Synonyms
GaM
    Click to Show/Hide
MOA Binder
External Link
CID: 9846339
TTD: D05ACQ
DrugBank: DB05420
 Compound Name MDL 101,731 Discontinued in Phase 2 [10]
Synonyms
Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331
    Click to Show/Hide
MOA Modulator
External Link
CID: 6435808
TTD: D05HZI
DrugBank: DB06433
 Compound Name NKP-46 Preclinical [11]
Synonyms
FFC-11; KP-46
    Click to Show/Hide
External Link
TTD: D0V2RK
References
Ref 1 The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer. Nat Commun. 2020 Jun 25;11(1):3214. doi: 10.1038/s41467-020-17007-9.
Ref 2 HNRNPA2B1 Affects the Prognosis of Esophageal Cancer by Regulating the miR-17-92 Cluster. Front Cell Dev Biol. 2021 Jun 30;9:658642. doi: 10.3389/fcell.2021.658642. eCollection 2021.
Ref 3 MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway. Mol Cell Biochem. 2021 Feb;476(2):689-698. doi: 10.1007/s11010-020-03936-y. Epub 2020 Oct 30.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 5 PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
Ref 6 Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
Ref 7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 8 Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
Ref 9 Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1739-43.
Ref 10 Tezacitabine Hoechst Marion Roussel.Curr Opin Investig Drugs.2000 Sep;1(1):135-40.
Ref 11 Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. J Clin Oncol (Meeting Abstracts) June 2005 vol. 23 no. 16_suppl 3205.